Janux Therapeutics (JANX) Projected to Post Earnings on Friday

Janux Therapeutics (NASDAQ:JANX - Get Free Report) is anticipated to announce its earnings results before the market opens on Friday, March 14th. Analysts expect the company to announce earnings of ($0.49) per share for the quarter.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. On average, analysts expect Janux Therapeutics to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Janux Therapeutics Trading Down 1.4 %

Janux Therapeutics stock traded down $0.42 during mid-day trading on Monday, reaching $30.22. The company's stock had a trading volume of 859,549 shares, compared to its average volume of 818,445. Janux Therapeutics has a twelve month low of $29.54 and a twelve month high of $71.71. The business has a 50 day moving average price of $41.27 and a 200-day moving average price of $47.50. The firm has a market cap of $1.79 billion, a price-to-earnings ratio of -25.83 and a beta of 3.23.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on JANX. Cantor Fitzgerald reissued an "overweight" rating and issued a $200.00 target price on shares of Janux Therapeutics in a report on Wednesday, December 11th. Leerink Partners raised their price target on Janux Therapeutics from $79.00 to $91.00 and gave the stock an "outperform" rating in a report on Tuesday, December 3rd. Lifesci Capital upgraded Janux Therapeutics to a "strong-buy" rating in a research note on Friday, December 27th. Leerink Partnrs raised shares of Janux Therapeutics to a "strong-buy" rating in a report on Friday, November 22nd. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $70.00 price objective on shares of Janux Therapeutics in a report on Monday, March 3rd. One equities research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $88.00.

Remove Ads

Insider Buying and Selling at Janux Therapeutics

In related news, Director Ra Capital Management, L.P. bought 341,742 shares of the firm's stock in a transaction that occurred on Wednesday, March 5th. The shares were acquired at an average cost of $30.64 per share, for a total transaction of $10,470,974.88. Following the acquisition, the director now directly owns 9,658,988 shares of the company's stock, valued at $295,951,392.32. The trade was a 3.67 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Andrew Hollman Meyer sold 13,334 shares of the firm's stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $54.88, for a total transaction of $731,769.92. Following the completion of the transaction, the insider now directly owns 82,139 shares of the company's stock, valued at $4,507,788.32. This represents a 13.97 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 50,002 shares of company stock valued at $2,684,703. 29.40% of the stock is owned by insiders.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.